Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Drug- Drug Interaction Study of JI-101 and Everolimus in Patients With Advanced Solid Tumors Refractory to Therapy With an Expansion Pharmacodynamic Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Next Previous
Search
Trial Profile

A Drug- Drug Interaction Study of JI-101 and Everolimus in Patients With Advanced Solid Tumors Refractory to Therapy With an Expansion Pharmacodynamic Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JI 101 (Primary) ; Everolimus
  • Indications Colorectal cancer; Head and neck cancer; Ovarian cancer; Solid tumours
  • Focus Pharmacogenomic; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 14 Sep 2015 Results (single agent in an ovarian cancer expansion cohort) published in the Investigational New Drugs.
    • 14 Aug 2012 Actual end date (August 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top